My Screeners
No screeners
System Screeners
My Watchlists
No watchlists
System Watchlists
Loading...
Azora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered, colon-targeted therapies for immune-mediated inflammatory diseases. Following its 2026 merger and name change from Adial Pharmaceuticals, its core business centers on AT177, a fully synthetic aryl hydrocarbon receptor (AhR) agonist being advanced toward clinical proof-of-concept in ulcerative colitis, with planned expansion into Crohn's disease. The company no longer develops addiction- or alcohol-use disorder candidates, which were part of its legacy business.
AT177 is designed to restore mucosal immune homeostasis in the colon while minimizing systemic exposure to reduce potential side effects. It is a prodrug that delivers indirubin, the active AhR agonist derived from the botanical extract indigo naturalis. Azora is conducting IND-enabling studies for AT177, with an Investigational New Drug submission and commencement of a Phase 1a single- and multiple-ascending-dose clinical trial planned for the first half of 2027.
The company owns worldwide royalty-free rights to its AT177 technology, which emerged from Stanford University's SPARK translational medicine program. Azora's operations are based in Encino, California. It does not yet generate revenue from approved products and funds its development through capital raising, potential licensing, or strategic partnerships. Its research and manufacturing efforts include preclinical studies, GLP toxicology, GMP-compliant manufacturing, and regulatory submissions.
Click to see warnings
Effective scoring profile: Not scored
No derived inputs, proxies, or historical consensus fills affected these scores.
Log in to see details
Log in for full accessIt is important that you understand how Findx arrives at Fair Value. Please take a minute to watch this short explainer.
It is very important that you understand this
Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.